Легочная форма туберкулеза

Список литературы

Основные статьи

World Health Organization. Treatment of tuberculosis: guidelines for national programmes. 4th edition. 2010 [internet publication].Полный текст

Uthman OA, Okwundu C, Gbenga K, et al. Optimal timing of antiretroviral therapy initiation for HIV-infected adults with newly diagnosed pulmonary tuberculosis: a systematic review and meta-analysis. Ann Intern Med. 2015 Jul 7;163(1):32-9. Аннотация

Tuberculosis Trials Consortium. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet. 2002 Aug 17;360(9332):528-34. Аннотация

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Controlling tuberculosis in the United States. Am J Respir Crit Care Med. 2005 Nov 1;172(9):1169-227.Полный текст  Аннотация

Статьи, указанные как источники

1. World Health Organization. Global tuberculosis report 2019. Oct 2019 [internet publication].Полный текст

2. Dye C. Global epidemiology of tuberculosis. Lancet. 2006 Mar 18;367(9514):938-40. Аннотация

3. Mancuso JD, Diffenderfer JM, Ghassemieh BJ, et al. The Prevalence of Latent Tuberculosis Infection in the United States. Am J Respir Crit Care Med. 2016 Aug 15;194(4):501-9.Полный текст  Аннотация

4. Schwartz NG, Price SF, Pratt RH, et al. Tuberculosis - United States, 2019. MMWR Morb Mortal Wkly Rep. 2020 Mar 20;69(11):286-9.Полный текст  Аннотация

5. Lienhardt C. From exposure to disease: the role of environmental factors in susceptibility to an development of tuberculosis. Epidemiol Rev. 2001 Jul;23(2):288-301. Аннотация

6. Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016 Oct 1;63(7):e147-95.Полный текст  Аннотация

7. Lin HH, Ezzati M, Murray M. Tobacco smoke, indoor air pollution and tuberculosis: a systematic review and meta-analysis. PLoS Med. 2007 Jan;4(1):e20.Полный текст  Аннотация

8. Marks SM, Taylor Z, Qualls NL, et al. Outcomes of contact investigations of infectious tuberculosis patients. Am J Respir Crit Care Med. 2000 Dec;162(6):2033-8.Полный текст  Аннотация

9. Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017 Jan 15;64(2):e1-e33.Полный текст  Аннотация

10. Zuber PL, McKenna MT, Binkin NJ, et al. Long-term risk of tuberculosis among foreign-born persons in the United States. JAMA. 1997 Jul 23-30;278(4):304-7. Аннотация

11. Markowitz N, Hansen NI, Hopewell PC, et al. Incidence of tuberculosis in the United States among HIV-infected persons. Ann Intern Med. 1997 Jan 15;126(2):123-32. Аннотация

12. Toossi Z, Mayanja-Kizza H, Hirsch CS, et al. Impact of tuberculosis on HIV-1 activity in dually infected patients. Clin Exp Immunol. 2001 Feb;123(2):233-8.Полный текст  Аннотация

13. Daley CL, Small PM, Schechter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with human immunodeficiency syndrome. N Engl J Med. 1992 Jan 23;326(4):231-5. Аннотация

14. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989 Mar 2;320(9):545-50. Аннотация

15. Jick SS, Lieberman ES, Rahman MU, et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum. 2006 Feb 15;55(1):19-26. Аннотация

16. Wallis RS, Broder MS, Wong JY, et al. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis. 2004 Oct 15;39(8):1254-5. Аннотация

17. Kamboj M, Sepkowitz KA. The risk of tuberculosis in patients with cancer. Clin Infect Dis. 2006 Jun 1;42(11):1592-5. Аннотация

18. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 2):S221-47.Полный текст  Аннотация

19. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ. 1982;60(4):555-64. Аннотация

20. Cantwell MF, McKenna MT, McCray E, et al. Tuberculosis and race/ethnicity in the United States, impact of socioeconomic status. Am J Respir Crit Care Med. 1998 Apr;157(4 Pt 1):1016-20.Полный текст  Аннотация

21. Colditz GA, Berkey CS, Mosteller F, et al. The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics. 1995 Jul;96(1 Pt 1):29-35. Аннотация

22. Mangtani P, Abubakar I, Ariti C, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis. 2014 Feb;58(4):470-80.Полный текст  Аннотация

23. Katelaris AL, Jackson C, Southern J, et al. Effectiveness of BCG Vaccination Against Mycobacterium tuberculosis Infection in Adults: A Cross-sectional Analysis of a UK-Based Cohort. J Infect Dis. 2020 Jan 1;221(1):146-55.Полный текст  Аннотация

24. Centers for Disease Control and Prevention (CDC). Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb Mortal Wkly Rep. 2009 Jan 16;58(1):7-10.Полный текст  Аннотация

25. Loto OM, Awowole I. Tuberculosis in pregnancy: a review. J Pregnancy. 2012 Nov 1;2012:379271.Полный текст  Аннотация

26. Behr MA, Warren SA, Salamon H, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet. 1999 Feb 6;353(9151):444-9. Аннотация

27. Horne DJ, Kohli M, Zifodya JS, et al. Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2019 Jun 7;(6):CD009593.Полный текст  Аннотация

28. Metcalfe JZ, Everett CK, Steingart KR, et al. Interferon-γ release assays for active pulmonary tuberculosis diagnosis in adults in low- and middle-income countries: systematic review and meta-analysis. J Infect Dis. 2011 Nov 15;204 (Suppl 4):S1120-9.Полный текст  Аннотация

29. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008 Aug 5;149(3):177-84. Аннотация

30. Mazurek GH, Jereb J, Vernon A, et al; IGRA Expert Committee; Centers for Disease Control and Prevention (CDC). Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep. 2010 Jun 25;59(RR-5):1-25.Полный текст  Аннотация

31. Doherty SD, Van Voorhees A, Lebwohl MG, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol. 2008 Aug;59(2):209-17. Аннотация

32. Miller LG, Asch SM, Yu EI, et al. A population-based survey of tuberculosis symptoms: how atypical are atypical presentations. Clin Infect Dis. 2000 Feb;30(2):293-9. Аннотация

33. Geng E, Kreiswirth B, Burzynski J, et al. Clinical and radiographic correlates of primary and reactivation tuberculosis, a molecular epidemiology study. JAMA. 2005 Jun 8;293(22):2740-5. Аннотация

34. Jones BE, Ryu R, Yang Z, et al. Chest radiographic findings in patients with tuberculosis with recent or remote infection. Am J Respir Crit Care Med. 1997 Oct;156(4 Pt 1):1270-3.Полный текст  Аннотация

35. Global Laboratory Initiative. Mycobacteriology laboratory manual. Apr 2014 [internet publication].Полный текст

36. Garay SM. Pulmonary tuberculosis. In: Rom WM, Garay SM, eds. Tuberculosis. 2nd ed. New York: Lippincott, Williams & Wilkins; 2003:345-94.

37. Pai M, Menzies D. Interferon-release assays: what is their role in the diagnosis of active tuberculosis. Clin Infect Dis. 2007 Jan 1;44(1):74-7. Аннотация

38. Dewan PK, Grinsdale J, Kawamura LM. Low sensitivity of a whole-blood interferon-gamma release assay for detection of active tuberculosis. Clin Infect Dis. 2007 Jan 1;44(1):69-73. Аннотация

39. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010 Sep 9;363(11):1005-15.Полный текст  Аннотация

40. Centers for Disease Control and Prevention. Tuberculosis (TB) (Mycobacterium tuberculosis) 2009 case definition. 2009 [internet publication].Полный текст

41. World Health Organization. Definitions and reporting framework for tuberculosis - 2013 revision. Dec 2014 [internet publication].Полный текст

42. US Preventive Services Task Force. Final recommendation statement latent tuberculosis infection: screening. Sept 2016 [internet publication].Полный текст

43. Sosa LE, Njie GJ, Lobato MN, et al. Tuberculosis screening, testing, and treatment of U.S. health care personnel: recommendations from the National Tuberculosis Controllers Association and CDC, 2019. MMWR Morb Mortal Wkly Rep. 2019 May 17;68(19):439-43.Полный текст  Аннотация

44. World Health Organization. Systematic screening for active tuberculosis: principles and recommendations. 2013 [internet publication].Полный текст

45. World Health Organization. WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment. 2020. Полный текст

46. Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2019 Nov 15;200(10):e93-142.Полный текст  Аннотация

47. Karumbi J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev. 2015 May 29;2015(5):CD003343.Полный текст  Аннотация

48. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. 4th edition. 2010 [internet publication].Полный текст

49. Jasmer RM, Seaman CB, Gonzalez L, et al. Tuberculosis treatment outcomes: Directly observed therapy compared with self administered therapy. Am J Respir Crit Care Med. 2004 Sep 1;170(5):561-6.Полный текст  Аннотация

50. Critchley JA, Orton LC, Pearson F. Adjunctive steroid therapy for managing pulmonary tuberculosis. Cochrane Database Syst Rev. 2014 Nov 12;2014(11):CD011370.Полный текст  Аннотация

51. Gopalan N, Santhanakrishnan RK, Palaniappan AN, et al. Daily vs intermittent antituberculosis therapy for pulmonary tuberculosis in patients with HIV: A randomized clinical trial. JAMA Intern Med. 2018 Apr 1;178(4):485-93. Аннотация

52. World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. Nov 2009 [internet publication].Полный текст

53. Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010 Jul 15;363(3):257-65.Полный текст  Аннотация

54. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010 Feb 25;362(8):697-706.Полный текст  Аннотация

55. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 2011 Oct 20;365(16):1492-501.Полный текст  Аннотация

56. Havlir DV, Kendall MA, Ive P, et al; AIDS Clinical Trials Group Study A5221. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011 Oct 20;365(16):1482-91.Полный текст  Аннотация

57. Uthman OA, Okwundu C, Gbenga K, et al. Optimal timing of antiretroviral therapy initiation for HIV-infected adults with newly diagnosed pulmonary tuberculosis: a systematic review and meta-analysis. Ann Intern Med. 2015 Jul 7;163(1):32-9. Аннотация

58. Manosuthi W, Kiertiburanakul S, Phoorisri T, et al. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J Infect. 2006 Dec;53(6):357-63. Аннотация

59. US Food and Drug Administration. FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. Dec 2018 [internet publication].Полный текст

60. US Food & Drug Administraton. FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes. Jul 2018 [internet publication].Полный текст

61. World Health Organization. WHO consolidated guidelines on tuberculosis, module 4: treatment - drug-resistant tuberculosis treatment. 2020 [internet publication]Полный текст

62. World Health Organization. Tuberculosis (TB). Frequently asked questions - XDR-TB. 2020 [internet publication].Полный текст

63. Tuberculosis Trials Consortium. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet. 2002 Aug 17;360(9332):528-34. Аннотация

64. Centers for Disease Control and Prevention; National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. Feb 2020.Полный текст  Аннотация

65. East and Central African/British Medical Research Council Fifth Collaborative Study. Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-months and one 8-month) for pulmonary tuberculosis. Tubercle. 1986 Mar;67(1):5-15. Аннотация

66. British Thoracic Society. A controlled trial of 6 months chemotherapy in pulmonary tuberculosis, final report: results during the 36 months after the end of chemotherapy and beyond. Br J Dis Chest. 1984 Oct;78(4):330-6. Аннотация

67. Conradie F, Diacon AH, Ngubane N, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med. 2020 Mar 5;382(10):893-902.Полный текст  Аннотация

68. Anyama N, Bracebridge S, Black C, et al. What happens to people diagnosed with tuberculosis? A population-based cohort. Epidemiol Infect. 2007 Oct;135(7):1069-76. Аннотация

69. Fielder JF, Chaulk CP, Dalvi M, et al. A high tuberculosis case-fatality rate in a setting of effective tuberculosis control: implications for acceptable treatment success rates. Int J Tuberc Lung Dis. 2002 Dec;6(12):1114-7. Аннотация

70. Penner C, Roberts D, Kunimoto D, et al. Tuberculosis as a primary cause of respiratory failure requiring mechanical ventilation. Am J Respir Crit Care Med. 1995 Mar;151(3 Pt 1):867-72. Аннотация

71. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Controlling tuberculosis in the United States. Am J Respir Crit Care Med. 2005 Nov 1;172(9):1169-227.Полный текст  Аннотация

72. Narita M, Ashkin D, Hollender ES, et al. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med. 1998 Jul;158(1):157-61.Полный текст  Аннотация

73. Cheng V, Ho P, Lee R, et al. Clinical spectrum of paradoxical deterioration during antituberculosis therapy in non-HIV-infected patients. Eur J Clin Microbiol Infect Dis. 2002 Nov;21(11):803-9. Аннотация

74. Santiago S, Tobias J, Williams AJ. A reappraisal of the causes of hemoptysis. Arch Intern Med. 1991 Dec;151(12):2449-51. Аннотация

75. Johnston H, Reisz G. Changing spectrum of hemoptysis. Underlying causes in 148 patients undergoing diagnostic flexible fiberoptic bronchoscopy. Arch Intern Med. 1989 Jul;149(7):1666-8. Аннотация

76. World Health Organization. Tuberculosis and air travel: guidelines for prevention and control. 2008 [internet publication].Полный текст

77. Abubakar I, Fernandez de la Hoz K. WHO publishes the third edition of guidelines for the prevention and control of air-travel-associated tuberculosis. Euro Surveill. 2008 Jun 5;13(23):18898.Полный текст  Аннотация

Использование этого контента попадает под действие нашего заявления об отказе от ответственности